Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719471 | 0.99 | ALDH1A1 (0.47) | ALDH1A1KMT2AHSD17B10HTTL3MBTL1 | |
| SCHEMBL3994258 | 0.99 | ALDH1A1 (0.47) | ALDH1A1KMT2AHSD17B10HTTL3MBTL1 | |
| SCHEMBL1719387 | 0.96 | ALDH1A1 (0.40) | ALDH1A1KMT2AHSD17B10HTTL3MBTL1 | |
| SCHEMBL1720086 | 0.91 | SMN1; SMN2 (0.40) | ALDH1A1KMT2AHSD17B10HTTMEN1 | |
| SCHEMBL1719815 | 0.85 | ALDH1A1 (0.39) | ALDH1A1KMT2AHSD17B10KDM4EMEN1 | |
| SCHEMBL1720297 | 0.82 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1MAPK1SMN1; SMN2NPC1 | |
| SCHEMBL1719384 | 0.80 | KMT2A (0.35) | ALDH1A1KMT2AKDM4EMEN1GAA | |
| SCHEMBL1719442 | 0.78 | MAPT (0.30) | KMT2AMAPT | |
| SCHEMBL1719852 | 0.77 | TSHR (0.35) | ALDH1A1KMT2AHTTL3MBTL1KDM4E | |
| SCHEMBL6990452 | 0.76 | ALDH1A1 (0.49) | ALDH1A1KMT2AHSD17B10HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2013-10-17 | — | — | US | claimed |
| EP-2452683-A2 | Methods for treating atherosclerosis | Amgen Inc. (US) | 2012-05-16 | — | — | EP | claimed |
| EP-2037928-B1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2012-01-11 | — | — | EP | claimed |
| US-20080096900-A1 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2008-04-24 | — | — | US | claimed |
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8426358-B2 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2452683-A2 | Methods for treating atherosclerosis | Amgen Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2037928-B1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2037928-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | Amgen Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080096900-A1 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008002591-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | LCAT, PCSK9, CETP | ALDH1A1 2876/4885KMT2A 2382/4885HSD17B10 405/4885 |
| US-20080096900-A1 | Methods for treating atherosclerosis | LCAT, PCSK9, CETP | ALDH1A1 2876/4885KMT2A 2382/4885HSD17B10 405/4885 |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | LCAT, PCSK9, CETP | ALDH1A1 2876/4885KMT2A 2382/4885HSD17B10 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.